New Aspects in the Mechanism of Action of 3-hydroxy-3-methylglutaryl-COA Reductase (HMG-CoA reductase): Cyclic Lactones - Potential Inhibitors of the Enzyme (Review)

References

1. RiyadP. PurohitA. SenK. PanwarA. RamH. HMG – CoA reductase inhibition mediated hypocholesterolemic potential of myricetin and quercetin: in-silico and in-vivo studies.CYTA J. Food202321111512510.1080/19476337.2022.2162976
   [Google Scholar]
2. ZhouY. TashiroJ. KamataniS. HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.Biochem. Biophys. Res. Commun.2023677131910.1016/j.bbrc.2023.07.056 37541087
   [Google Scholar]
3. PakV.V. KimS.H. KooM. LeeN. ShakhidoyatovK.M. KwonD.Y. Peptide design of a competitive inhibitor for HMG-CoA reductase based on statin structure.Biopolymers200684658659410.1002/bip.20580 16886212
   [Google Scholar]
4. SamizoS. KanekoH. Predictive Modeling of HMG-CoA Reductase Inhibitory Activity and Design of New HMG-CoA Reductase Inhibitors.ACS Omega2023830272472725510.1021/acsomega.3c02567 37546661
   [Google Scholar]
5. MarahathaR BasnetS BhattaraiB R Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis.BMC compl med therap2021211110.1186/s12906‑020‑03162‑5
   [Google Scholar]
6. BoseS. SteussyC.N. López-PérezD. Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor.Commun. Biol.20236136010.1038/s42003‑023‑04639‑y 37012403
   [Google Scholar]
7. OjhaS. IslamB. CharuC. AdemA. AburawiE. Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking.Drug Des. Devel. Ther.201594943495110.2147/DDDT.S86705 26357462
   [Google Scholar]
8. SuganyaS. NandagopalB. AnbarasuA. Natural inhibitors of HMG-CoA reductase—An in silico approach through molecular docking and simulation studies.J. Cell. Biochem.20171181525710.1002/jcb.25608 27216569
   [Google Scholar]
9. JaitrongM. BoonsriP. SamosornS. Molecular docking studies of berberine derivative as novel multitarget pcsk9 and hmgcr inhibitors.Science Essence Journal2021371124142
   [Google Scholar]
10. GarcíaI. FallY. GómezG. Review of synthesis, biological assay, and QSAR studies of HMGR inhibitors.Curr. Top. Med. Chem.201212889591910.2174/156802612800166729 22352916
    [Google Scholar]
11. Abu MellalA. HussainN. SaidA. The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies.Ther. Clin. Risk Manag.20191592193610.2147/TCRM.S214938 31413581
    [Google Scholar]
12. Gallego-ColonE. DaumA. YosefyC. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.Eur. J. Pharmacol.202087817311410.1016/j.ejphar.2020.173114 32302598
    [Google Scholar]
13. ParkM.S. YounJ.C. KimE.J. Efficacy and safety of fenofibrate-statin combination therapy in patients with inadequately controlled triglyceride levels despite previous statin monotherapy: A Multicenter, Randomized, double-blind, Phase IV study.Clin. Ther.202143101735174710.1016/j.clinthera.2021.08.005 34518033
    [Google Scholar]
14. EngellA.E. SvendsenA.L.O. LindB.S. Drug-drug interaction between warfarin and statins: A Danish cohort study.Br. J. Clin. Pharmacol.202187269469910.1111/bcp.14428 32533893
    [Google Scholar]
15. RuszkowskiP. Masajtis-ZagajewskaA. NowickiM. Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study.J. Renin Angiotensin Aldosterone Syst.201920310.1177/1470320319868890 31486700
    [Google Scholar]
16. KohK.K. SakumaI. ShimadaK. HayashiT. QuonM.J. Combining potent statin therapy with other drugs to optimize simultaneous cardiovascular and metabolic benefits while minimizing adverse events.Korean Circ. J.201747443243910.4070/kcj.2016.0406 28765731
    [Google Scholar]
17. MasanaL. IbarretxeD. PlanaN. Reasons Why Combination Therapy should be the new standard of care to achieve the LDL-cholesterol targets.Curr. Cardiol. Rep.20202286610.1007/s11886‑020‑01326‑w 32562015
    [Google Scholar]
18. ChungS. KoY.G. KimJ.S. Effect of FIXed-dose combination of ARb and statin on adherence and risk factor control: The randomized FIXAR study.Cardiol. J.202229581582310.5603/CJ.a2020.0167 33346375
    [Google Scholar]
19. AlmalkiH.H. AlshibaniT.M. AlhifanyA.A. AlmohammedO.A. Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: a network meta-analysis of randomized clinical trials.BMC Womens Health20202016810.1186/s12905‑020‑00919‑5 32248801
    [Google Scholar]
20. RheeM.Y. KimC.H. AhnY. Efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with concomitant hypertension and hyperlipidemia.Drug Des. Devel. Ther.2020145005501710.2147/DDDT.S280055 33235439
    [Google Scholar]
21. VögeliB. ShimaS. ErbT.J. WagnerT. Crystal structure of archaeal HMG -CoA reductase: insights into structural changes of the C-terminal helix of the class-I enzyme.FEBS Lett.2019593554355310.1002/1873‑3468.13331 30702149
    [Google Scholar]
22. LinF. DasD. LinX.N. MarshE.N.G. Aldehyde-forming fatty acyl-C o A reductase from cyanobacteria: expression, purification and characterization of the recombinant enzyme.FEBS J.2013280194773478110.1111/febs.12443 23895371
    [Google Scholar]
23. HainesB.E. WiestO. StauffacherC.V. The increasingly complex mechanism of HMG-CoA reductase.Acc. Chem. Res.201346112416242610.1021/ar3003267 23898905
    [Google Scholar]
24. GestoD.S. PereiraC.M.S. CerqueiraN.M.F.S. SousaS.F. An atomic-level perspective of HMG-CoA-reductase: The target enzyme to treat hypercholesterolemia.Molecules20202517389110.3390/molecules25173891 32859023
    [Google Scholar]
25. MushkabarovN.N. Moscow - Flinta: Monograph. Publisher 2020.Metabolism: structural-chemical and thermodynamic analysis: in 3 vol.Moscow - Flinta: Monograph. Publisher2020
    [Google Scholar]
26. YogevY. ShorerZ. KoifmanA. Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone.Proc. Natl. Acad. Sci. USA20231207e221783112010.1073/pnas.2217831120 36745799
    [Google Scholar]
27. Gómez-BombarelliR. CalleE. CasadoJ. Mechanisms of lactone hydrolysis in acidic conditions.J. Org. Chem.201378146880688910.1021/jo4002596 23731203
    [Google Scholar]
28. FatokiT.H. Effect of pH on structural dynamics of HMG-CoA reductase and binding affinity to β-sitosterol.J. Biomol. Struct. Dyn.202341104398440410.1080/07391102.2022.2067240 35470784
    [Google Scholar]
29. HoutenS.M. SchneidersM.S. WandersR.J.A. WaterhamH.R. Regulation of isoprenoid/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients.J. Biol. Chem.200327885736574310.1074/jbc.M206564200 12477733
    [Google Scholar]
30. McCloryJ. LinJ.T. TimsonD.J. ZhangJ. HuangM. Catalytic mechanism of mevalonate kinase revisited, a QM/MM study.Org. Biomol. Chem.20191792423243110.1039/C8OB03197E 30735219
    [Google Scholar]
31. EdwardsP.A. LanS.F. TanakaR.D. FogelmanA.M. Mevalonolactone inhibits the rate of synthesis and enhances the rate of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat hepatocytes.J. Biol. Chem.1983258127272727510.1016/S0021‑9258(18)32171‑9 6863245
    [Google Scholar]
32. ChenT. GaoY. ZhangS. WangY. SuiC. YangL. Methylmalonic acidemia: Neurodevelopment and neuroimaging.Front. Neurosci.202317111094210.3389/fnins.2023.1110942 36777632
    [Google Scholar]
33. ZhouX. CuiY. HanJ. Methylmalonic acidemia: Current status and research priorities.Intractable Rare Dis. Res.201872737810.5582/irdr.2018.01026 29862147
    [Google Scholar]
34. GoedekeL. Canfrán-DuqueA. RotllanN. MMAB promotes negative feedback control of cholesterol homeostasis.Nat. Commun.2021121644810.1038/s41467‑021‑26787‑7 34750386
    [Google Scholar]
35. GermanC.A. LiaoJ.K. Understanding the molecular mechanisms of statin pleiotropic effects.Arch. Toxicol.20239761529154510.1007/s00204‑023‑03492‑6 37084080
    [Google Scholar]
36. LeeY.J. HongS.J. KangW.C. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial.BMJ2023383e07583710.1136/bmj‑2023‑075837 37852649
    [Google Scholar]
37. AdamsS.P. AlaeiilkhchiN. TasnimS. WrightJ.M. Pravastatin for lowering lipids.Cochrane Libr.202099CD01367310.1002/14651858.CD013673 37721222
    [Google Scholar]
38. AdamsS.P. TielletN. AlaeiilkhchiN. WrightJ.M. Cerivastatin for lowering lipids.Cochrane Libr.202011CD01250110.1002/14651858.CD012501.pub2 31981471
    [Google Scholar]
39. Pinal-FernandezI. Casal-DominguezM. MammenA.L. Statins: pros and cons.Med. Clin. (Barc.)20181501039840210.1016/j.medcli.2017.11.030 29292104
    [Google Scholar]
40. PretaG. Role of Lactone and Acid Forms in the Pleiotropic Effects of Statins.Pharmaceutics2022149189910.3390/pharmaceutics14091899 36145647
    [Google Scholar]
41. YinW. AlwabliR.I. AttwaM.W. RahmanA.F.M.M. KadiA.A. Simvastatin: In vitro metabolic profiling of a potent competitive HMG-CoA reductase inhibitor.Separations202291240010.3390/separations9120400
    [Google Scholar]
42. BalasubramanianR. MaideenN.M.P. HMG-CoA reductase inhibitors (Statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview.Curr. Drug Metab.202122532834110.2174/18755453MTEz9MzEj5 33459228
    [Google Scholar]
43. YeeJ. KimH. HeoY. YoonH.Y. SongG. GwakH.S. Association between CYP3A5 polymorphism and statin-induced adverse events: A systemic review and meta-analysis.J. Pers. Med.202111767710.3390/jpm11070677 34357144
    [Google Scholar]
44. ZhengE MaduraP GrandosJ When the same treatment has different response: The role of pharmacogenomics in statin therapy.Biomed pharmacoth202417011596610.1016/j.biopha.2023.115966
    [Google Scholar]
45. YowH Y HamzahS Abdul RahimN SuppiahV. Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review.As biomed20231739511410.2478/abm‑2023‑0050
    [Google Scholar]
46. NeuvonenP.J. BackmanJ.T. NiemiM. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.Clin. Pharmacokinet.200847746347410.2165/00003088‑200847070‑00003 18563955
    [Google Scholar]
47. ParkJ.E. KimK.B. BaeS.K. MoonB.S. LiuK.H. ShinJ.G. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin.Xenobiotica20083891240125110.1080/00498250802334391 18720283
    [Google Scholar]
48. GorabiA.M. KiaieN. HajighasemiS. Statin-induced nitric oxide signaling: mechanisms and therapeutic implications.J. Clin. Med.2019812205110.3390/jcm8122051 31766595
    [Google Scholar]
49. TennakoonM. KankanamgeD. SenarathK. FasihZ. KarunarathneA. Statins perturb G βγ signaling and cell behavior in a G γ subtype dependent manner.Mol. Pharmacol.201995436137510.1124/mol.118.114710 30765461
    [Google Scholar]
50. NennaA. NappiF. LusiniM. Effect of statins on platelet activation and function: from molecular pathways to clinical effects.BioMed Res. Int.2021202111010.1155/2021/6661847 33564680
    [Google Scholar]
51. SikoraJ. KostkaB. MarczykI. KrajewskaU. ChałubińskiM. BroncelM. Effect of statins on platelet function in patients with hyperlipidemia.Arch. Med. Sci.20134462262810.5114/aoms.2013.36905 24049520
    [Google Scholar]
52. SafitriN. AlainaM.F. PitalokaD.A.E. AbdulahR. A narrative review of statin-induced rhabdomyolysis: molecular mechanism, risk factors, and management.Drug Healthc. Patient Saf.20211321121910.2147/DHPS.S333738 34795533
    [Google Scholar]
53. DohlmannT.L. KuhlmanA.B. MorvilleT. Coenzyme Q10 supplementation in statin treated patients: A double-blinded randomized placebo-controlled trial.Antioxidants2022119169810.3390/antiox11091698 36139772
    [Google Scholar]
54. CoenzymeQ. 10 and statin-related myopathy.Drug Ther. Bull.2015535545610.1136/dtb.2015.5.0325
    [Google Scholar]
55. EzadS. CheemaH. CollinsN. Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction.Oxf. Med. Case Rep.201820183omx10410.1093/omcr/omx104 29593874
    [Google Scholar]
56. ChenC.W. LeimerN. SyroeginE.A. Structural insights into the mechanism of overcoming Erm-mediated resistance by macrolides acting together with hygromycin-A.Nat. Commun.2023141419610.1038/s41467‑023‑39653‑5 37452045
    [Google Scholar]
57. Miklasińska-MajdanikM. Mechanisms of resistance to macrolide antibiotics among Staphylococcus aureus.Antibiotics (Basel)20211011140610.3390/antibiotics10111406 34827344
    [Google Scholar]
58. FyfeC. GrossmanT.H. KersteinK. SutcliffeJ. Resistance to macrolide antibiotics in public health pathogens.Cold Spring Harb. Perspect. Med.2016610a02539510.1101/cshperspect.a025395 27527699
    [Google Scholar]
59. DesjardinsM. DelgatyK.L. RamotarK. SeetaramC. ToyeB. Prevalence and mechanisms of erythromycin resistance in group A and group B Streptococcus: implications for reporting susceptibility results.J. Clin. Microbiol.200442125620562310.1128/JCM.42.12.5620‑5623.2004 15583291
    [Google Scholar]
60. ChiouC.S. HongY.P. WangY.W. Antimicrobial resistance and mechanisms of azithromycin resistance in nontyphoidal salmonella isolates in Taiwan, 2017 to 2018.Microbiol. Spectr.2023111e03364e2210.1128/spectrum.03364‑22 36688703
    [Google Scholar]
61. HeidaryM. Ebrahimi SamanganiA. KargariA. Mechanism of action, resistance, synergism, and clinical implications of azithromycin.J. Clin. Lab. Anal.2022366e2442710.1002/jcla.24427 35447019
    [Google Scholar]
62. ReygaertW C An overview of the antimicrobial resistance mechanisms of bacteria.AIMS microbiology4348250110.3934/microbiol.2018.3.482
    [Google Scholar]
63. MaslubM.G. RadwanM.A. DaudN.A.A. Sha’abanA. Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?Eur. J. Med. Res.202328138110.1186/s40001‑023‑01038‑1 37759317
    [Google Scholar]
64. HennessyE. AdamsC. ReenF.J. O’GaraF. Is there potential for repurposing statins as novel antimicrobials?Antimicrob. Agents Chemother.20166095111512110.1128/AAC.00192‑16 27324773
    [Google Scholar]
65. WeiZ. LiT. GuY. Design, synthesis, and biological evaluation of N-acyl-homoserine lactone analogs of quorum sensing in Pseudomonas aeruginosa.Front Chem.20221094868710.3389/fchem.2022.948687 35873042
    [Google Scholar]
66. HennessyE. MooijM.J. LegendreC. Statins inhibit in vitro virulence phenotypes of Pseudomonas aeruginosa.J. Antibiot. (Tokyo)20136629910110.1038/ja.2012.95 23149514
    [Google Scholar]
67. ZhangY. ChenZ. WenQ. An overview on the biosynthesis and metabolic regulation of monacolin K/lovastatin.Food Funct.20201175738574810.1039/D0FO00691B 32555902
    [Google Scholar]
68. El-TantawyW.H. Biochemical effects, hypolipidemic and anti-inflammatory activities of Artemisia vulgaris extract in hypercholesterolemic rats.J. Clin. Biochem. Nutr.2015571333810.3164/jcbn.14‑141 26236098
    [Google Scholar]
69. KonovalovD.A. ShevchukO.M. LogvinenkoL.A. KhamiloA.A. Biologically active compounds of annual wormwood. Sesquiterpene lactones.Pharmacy & Pharmacology20164543510.19163/2307‑9266‑2016‑4‑5‑4‑35
    [Google Scholar]
70. El MihyaouiA. Esteves da SilvaJ.C.G. CharfiS. Candela CastilloM.E. LamartiA. ArnaoM.B. Chamomile (Matricaria chamomilla L.): A review of ethnomedicinal use, phytochemistry and pharmacological uses.Life202212447910.3390/life12040479 35454969
    [Google Scholar]
71. AyoobiF. ShamsizadehA. FatemiI. Bio-effectiveness of the main flavonoids of Achillea millefolium in the pathophysiology of neurodegenerative disorders- a review.Iran. J. Basic Med. Sci.201720660461210.22038/IJBMS.2017.8827 28868116
    [Google Scholar]
72. VillalvaM. SilvanJ.M. Alarcón-CaveroT. Antioxidant, anti-inflammatory, and antibacterial properties of an Achillea millefolium L. extract and its fractions obtained by supercritical anti-solvent fractionation against Helicobacter pylori.Antioxidants20221110184910.3390/antiox11101849 36290572
    [Google Scholar]
73. RolnikA. OlasB. The plants of the Asteraceae family as agents in the protection of human health.Int. J. Mol. Sci.2021226300910.3390/ijms22063009 33809449
    [Google Scholar]
74. SokovićM. SkaltsaH. FerreiraI.C.F.R. Editorial: Bioactive phytochemicals in asteraceae: Structure, function, and biological activity.Front Plant Sci201910146410.3389/fpls.2019.01464 31798612
    [Google Scholar]
75. OzalpL. DanışÖ. Yuce-DursunB. DemirS. GündüzC. OganA. Investigation of HMG-CoA reductase inhibitory and antioxidant effects of various hydroxycoumarin derivatives.Arch Pharm202035310190037810.1002/ardp.201900378 32648617
    [Google Scholar]
76. AhmedM.G. MehmoodM.H. MehdiS. FarrukhM. Caryopteris odorata and its metabolite coumarin attenuate characteristic features of cardiometabolic syndrome in high-refined carbohydrate-high fat-cholesterol-loaded feed-fed diet rats.Front. Pharmacol.202314109740710.3389/fphar.2023.1097407 37033655
    [Google Scholar]
77. AgrawalS. HeissM.S. FenterR.B. Impact of CYP2C9-interacting drugs on warfarin pharmacogenomics.Clin. Transl. Sci.202013594194910.1111/cts.12781 32270628
    [Google Scholar]
78. ForoozeshM. SridharJ. GoyalN. LiuJ. Coumarins and P450s, studies reported to-date.Molecules2019248162010.3390/molecules24081620 31022888
    [Google Scholar]
79. LiJ WangS BaroneJ MaloneB. Warfarin pharmacogenomics.peer-rev j formul management20093484227
    [Google Scholar]
80. GuaschL. PeachM.L. NicklausM.C. Tautomerism of warfarin: combined chemoinformatics, quantum chemical, and NMR investigation.J. Org. Chem.201580209900990910.1021/acs.joc.5b01370 26372257
    [Google Scholar]
81. SoliemanabadS K RasouliK ZakariaeiZ SoleymaniM AliabadiP K Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction).Annal med surg20227510338410.1016/j.amsu.2022.103384
    [Google Scholar]
82. AzmiM.B. KhanF. AsifU. In silico characterization of Withania coagulans bioactive compounds as potential inhibitors of hydroxymethylglutaryl (HMG-CoA) reductase of Mus musculus.ACS Omega2023855057507110.1021/acsomega.2c07893 36777558
    [Google Scholar]
83. Flores-MoralesV. Villasana-RuízA.P. Garza-VelozI. González-DelgadoS. Martinez-FierroM.L. Therapeutic effects of coumarins with different substitution patterns.Molecules2023285241310.3390/molecules28052413 36903660
    [Google Scholar]
84. HarwoodH.J.Jr GreeneY.J. StacpooleP.W. Inhibition of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by ascorbic acid. An effect mediated by the free radical monodehydroascorbate.J. Biol. Chem.1986261167127713510.1016/S0021‑9258(17)38365‑5 3711081
    [Google Scholar]
85. AinembabaziD. ZhangY. TurchiJ.J. The mechanistic role of cardiac glycosides in DNA damage response and repair signalling. Cellular and molecular life sciences.Cell. Mol. Life Sci.202380925010.1007/s00018‑023‑04910‑9 37584722
    [Google Scholar]
86. PakV.V. KooM. KwonD.Y. YunL. Design of a highly potent inhibitory peptide acting as a competitive inhibitor of HMG-CoA reductase.Amino Acids20124352015202510.1007/s00726‑012‑1276‑0 22451276
    [Google Scholar]
87. Andrade-PavónD. Gómez-GarcíaO. Villa-TanacaL. Molecular recognition of citroflavonoids naringin and naringenin at the active site of the HMG-CoA reductase and DNA topoisomerase Type II Enzymes of Candida spp. and Ustilago maydis.Indian J. Microbiol.2022621798710.1007/s12088‑021‑00980‑0 35068607
    [Google Scholar]
88. SungJ.H. ChoiS.J. LeeS.W. ParkK.H. MoonT.W. Isoflavones found in Korean soybean paste as 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitors.Biosci. Biotechnol. Biochem.20046851051105810.1271/bbb.68.1051 15170109
    [Google Scholar]
89. LeopoldiniM. MalajN. ToscanoM. SindonaG. RussoN. On the inhibitor effects of bergamot juice flavonoids binding to the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) enzyme.J. Agric. Food Chem.20105819107681077310.1021/jf102576j 20843083
    [Google Scholar]
90. SrivastavaS. SonkarR. MishraS.K. Antidyslipidemic and antioxidant effects of novel Lupeol-derived chalcones.Lipids201348101017102710.1007/s11745‑013‑3824‑0 23943005
    [Google Scholar]
91. SunP. ZhaoL. ZhangN. Bioactivity of dietary polyphenols: the role in LDL-C lowering.Foods20211011266610.3390/foods10112666 34828946
    [Google Scholar]
92. BurseA. FrickS. SchmidtA. Implication of HMGR in homeostasis of sequestered and de novo produced precursors of the iridoid biosynthesis in leaf beetle larvae.Insect Biochem. Mol. Biol.2008381768810.1016/j.ibmb.2007.09.006 18070667
    [Google Scholar]
93. DhyaniP. SatiP. SharmaE. Sesquiterpenoid lactones as potential anti-cancer agents: an update on molecular mechanisms and recent studies.Cancer Cell Int.202222130510.1186/s12935‑022‑02721‑9 36207736
    [Google Scholar]
94. PaçoA. BrásT. SantosJ.O. SampaioP. GomesA.C. DuarteM.F. Anti-inflammatory and immunoregulatory action of sesquiterpene lactones.Molecules2022273114210.3390/molecules27031142 35164406
    [Google Scholar]
95. MazurM. MasłowiecD. Antimicrobial activity of lactones.Antibiotics20221110132710.3390/antibiotics11101327 36289985
    [Google Scholar]